Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study;L' "Effectiveness" degli antipsicotici nella schizofrenia e disturbi correlati. Risultati di uno studio naturalistico

Clinica Terapeutica

Volumn 162, Issue 4, 2011, Pages 331-341

  Carpiniello, B ^a   Mellino, G ^a   Pintore, S ^a   Puddu, L ^a   Pinna, F ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Atypical antipsychotics; Duration of treatment; Effectiveness; Treatment discontinuation; Typical antipsychotics

Indexed keywords

BUTYROPHENONE; CLOZAPINE; LONG ACTING DRUG; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; DELUSIONAL DISORDER; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NATURALISITIC STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BUTYROPHENONES; CLOZAPINE; DELAYED-ACTION PREPARATIONS; DELUSIONS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 81355123520     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Geddes J. Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overvìew and meta-regression analysis. Br Med J 2000; 321:1371-6
2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64
3. Glazer WM, Johnstone BM. Pharmacoecomomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58(Suppl 10):50-4
4. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory metaanalisys of randomized trials. Am J Psychiatry 2003;160:1209-22
5. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine vs. Haloperidol and placebo. Acute phase results of the American double-blind Olanzapine trial. Eur Neuropsychopharmacology 1996; 14:111-23
6. Tandon R, Flieschhacher WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79:145-55
7. Flieschhacher W, Widschwendter CG. Treatment of schizophrenia patients: comparing new-generation antipshotics to each other. Curr Opin Psychiatry 2006;19(2):128-34
8. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31-41
9. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373: 4-5
10. Fleischacker W, Goodwin GM. Effectiveness as an outcome measure for treatment trials in psychiatry. World Psych 2009; 8:23-7
11. Lieberman JA, Stroup TS, McEvoy JP et al, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med 2005; 353:1209-23
12. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600-10
13. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. Am J Psychiatry 2006; 163:611-22
14. Bilder K, Davis S, Stroup TS, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64:633-47
15. Stroup TS, Lieberman J, McEvoy, JP, et al. Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. Am J Psychiatry 2007; 164:415-27
16. Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE Found: Results From the Schizophrenia Trial. Psychiatr Serv 2008; 59:500-6
17. Heres S, Davis J, Leucht S. Why Olanzapine beats Risperidone Beats Quetiapine and quetiapine beats Olanzapine: comparison Studies of Second Generation Antipsychotics. Am J Psychiatry 2006; 163:185-94
18. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of Olanzapine, Quetiapine and Risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164:1050-60
19. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085-97
20. Rosenheck RA. Pharmacotherapy of first-episode schizophrenia. Lancet 2008; 371:1048-9
21. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods, and recruitment. Acta Psych Scand 2003; 107:222-32
22. Haro JM, David S. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study. Int Clin Psychopharmacology 2008; 23: 203-8
23. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007; 15:245-58
24. Ascher-Svanum H, Zhu B, Faries D, et al, Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia, BMC Psychiatry 2006; 6:8, doi:10.1186/1471-244X-6/8
25. Mojtabai R, Lavelle J, Gibson PJ, et al. Atypical antipsychotics in first admission schizophrenia:medication continuation and outcomes. Schizophrenia Bulletin 2003; 29:519-30
26. Gibson PJ, Damler R, Jackson EA, et al, The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004; 7:22-35
27. Carpiniello B, Pinna F. Disturbi dello spettro schizofrenico e differenze di genere: risultati di uno studio sugli aspetti clinici e terapeutici in un campione di pazienti ambulatoriali. Giorn Ital Psicopat 2005; 11:417-27
28. Brugnoli R, Frediani S, Rossi A. Incidenza e caratteristiche della remissione nei pazienti schizofrenici: analisi dei risultati a tre anni nei pazienti italiani dello studio SOHO. Giorn Ital Psicopat 2008; 14:243-51
29. Jones PB, Barnes TR, Davies L, et al. Randomized controller trial of the effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-86
30. Leucht S, Wahlbeck K Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics; a systematic review and meta-analysis. Lancet 2003; 361:1581-9
31. Carpiniello B, Corda E, Maccioni R, et al. Schizofrenia, obesità ed incremento ponderale associato alla farmacoterapia. La Clinica Terapeutica 2008; 159:299-306
32. Faries DE, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005; 5:26
33. Stephan H, Davis J, Leucht S. Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beat Olanzapine: an exploratory Analysis of Head Comparison Studies of Second- Generation Antipsychotics. Am J Psychiatry 2006; 163:185-95
34. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 2008;100:20-38
35. Davis SM, Koch GG, Davis CE, et al. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trial Effectiveness (CATIE) studies. Schizophrenia Bulletin 2003; 29:73-80
36. Moller KJ. Do " real world" studies on antipsychotics tell us the real truth? World Psychiatry 2009; 8:32
37. Wahlbeck K, Tuunainen A, Akokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacol 2001; 155:230-3
38. Weiss Ka, Smith TE, Hull JW et al, Predictors of non-adherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002; 28:341-9
39. Akkaya C, Sarandol A, Cangur K, et al. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting, Hum Psychopharmacol 2007; 22:515-28
40. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of ranbdomized trials. BMC Psychiatry 2088; 8:31
41. HaroJM, Edgell E, Belger M, et al, Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 2006; 21:41-7
42. Haro IM, Suarez D, Novick D, et al, Three year antipsychotic effectiveness in the otpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007; 17:235-44
43. Mullins CD, Obeidat NA, Cuffel BJ, et al, Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 2008; 98:8-15
44. Kinon BJ, Liu-Seifert H.Adams DH, et al. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006; 26:532-7